Deacetylase inhibitors: an advance in myeloma therapy?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Laubach, Jacob P. | - |
dc.contributor.author | San-Miguel, Jesus F. | - |
dc.contributor.author | Hungria, Vania | - |
dc.contributor.author | Hou, Jian | - |
dc.contributor.author | Moreau, Philippe | - |
dc.contributor.author | Lonial, Sagar | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Einsele, Hermann | - |
dc.contributor.author | Alsina, Melissa | - |
dc.contributor.author | Richardson, Paul G. | - |
dc.date.available | 2020-02-27T23:41:11Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1747-4086 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7441 | - |
dc.description.abstract | Introduction: A significant unmet need exists in patients with relapsed or refractory multiple myeloma ( MM), which remains an incurable disease despite recent advances in the field. One such development was the use of deacetylase inhibitors ( DACi), which exert unique antimyeloma effects through targeting of epigenetic and protein metabolism pathways. The pan-DACi panobinostat was recently approved in combination with bortezomib and dexamethasone for use in patients with relapsed or relapsed and refractory MM. Results of a phase 3 trial showed that the panobinostat-containing regimen improved the overall response rate and progression-free survival. Panobinostat-associated adverse events included thrombocytopenia, diarrhea, fatigue, and peripheral neuropathy. Research into how to maintain the benefits of DACi while improving tolerability is ongoing. Areas covered: This review focuses on the efficacy and safety of panobinostat and panobinostat-based combinations for MM. Early data from clinical trials investigating the HDAC6 inhibitor ricolinostat are also discussed. Expert commentary: DACi are a unique and effective new class of agents for the treatment of MM, with panobinostat being the first to have clinically meaningful benefit for patients with relapsed or refractory MM. Optimization of dose and schedule, novel combination strategies, and introduction of selective DACi may improve the risk-benefit profile of DACi-based regimens. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.relation.isPartOf | EXPERT REVIEW OF HEMATOLOGY | - |
dc.title | Deacetylase inhibitors: an advance in myeloma therapy? | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000394997100006 | - |
dc.identifier.doi | 10.1080/17474086.2017.1280388 | - |
dc.identifier.bibliographicCitation | EXPERT REVIEW OF HEMATOLOGY, v.10, no.3, pp.229 - 237 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85014618711 | - |
dc.citation.endPage | 237 | - |
dc.citation.startPage | 229 | - |
dc.citation.title | EXPERT REVIEW OF HEMATOLOGY | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Histone deacetylase inhibitor | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | panobinostat | - |
dc.subject.keywordAuthor | relapsed or relapsed and refractory | - |
dc.subject.keywordAuthor | ricolinostat | - |
dc.subject.keywordPlus | PANOBINOSTAT PLUS BORTEZOMIB | - |
dc.subject.keywordPlus | REFRACTORY MULTIPLE-MYELOMA | - |
dc.subject.keywordPlus | UNFOLDED PROTEIN RESPONSE | - |
dc.subject.keywordPlus | PROTEASOME INHIBITORS | - |
dc.subject.keywordPlus | HISTONE DEACETYLASES | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | LBH589 | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | VORINOSTAT | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.